Associated Genetic Biomarkers
Associated Diseases


Location [1]
Protein [2]
Myc proto-oncogene protein
Synonyms [1]
MRTL, bHLHe39, MYCC, c-Myc

The v-myc avian myelocytomatosis viral oncogene homolog (MYC) gene encodes a nuclear phosphoprotein that functions in cell cycle progression, apoptosis, and cellular transformation. The protein also functions as a transcription factor that controls gene expression. Missense mutations, silent mutations, frameshift deletions, and in-frame deletions are observed in cancers such as endometrial cancer, hematopoietic and lymphoid cancers, and stomach cancer.

MYC is altered in 3.89% of all cancers with breast invasive ductal carcinoma, lung adenocarcinoma, prostate adenocarcinoma, colon adenocarcinoma, and high grade ovarian serous adenocarcinoma having the greatest prevalence of alterations [3].

MYC GENIE Cases - Top Diseases

The most common alterations in MYC are MYC Amplification (3.62%), MYC Mutation (0.96%), MYC A59V (0.04%), MYC S161L (0.03%), and MYC G301D (0.02%) [3].

MYC GENIE Cases - Top Alterations

Biomarker-Directed Therapies

Significance of MYC in Diseases

Diffuse Large B-Cell Lymphoma +

Double-Hit Lymphoma +

Triple-Hit Lymphoma +

Transformed Non-Hodgkin Lymphoma +

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified +

B-Cell Non-Hodgkin Lymphoma +

Burkitt Lymphoma +

High Grade B-Cell Lymphoma, Not Otherwise Specified +

T-Cell/Histiocyte-Rich Large B-Cell Lymphoma +

Grade 3b Follicular Lymphoma +

High Grade B-Cell Lymphoma With MYC And BCL2 And/Or BCL6 Rearrangements +

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma +

Mantle Cell Lymphoma +

Primary Mediastinal B-Cell Lymphoma +

Non-Hodgkin Lymphoma +

Malignant Solid Tumor +

Mediastinal Large B-Cell Lymphoma +

Follicular Lymphoma +

EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified +

Hodgkin Lymphoma +

Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type +

ALK-Positive Large B-Cell Lymphoma +

Chronic Lymphocytic Leukemia +

Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation +

Marginal Zone Lymphoma +

Multiple Myeloma +

Breast Carcinoma +

Medulloblastoma +

Acute Lymphoblastic Leukemia +

Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma +

Intravascular Large B-Cell Lymphoma +

Lymphoma +

Non-Small Cell Lung Carcinoma +

Acute Myeloid Leukemia +

Burkitt Leukemia +

Diffuse Large B-Cell Lymphoma Activated B-Cell Type +

Mature B-Cell Lymphoma/Leukemia +

Medulloblastoma, Non-WNT/Non-SHH +

Richter Syndrome +

Ovarian Carcinoma +

Colorectal Carcinoma +

Central Nervous System Embryonal Neoplasm +

Anaplastic Astrocytoma +

Glioblastoma +

Central Nervous System Ganglioneuroblastoma +

Central Nervous System Neuroblastoma +

Gastrointestinal Stromal Tumor +

HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified +

Large B-Cell Lymphoma With IRF4 Rearrangement +

Lymphomatoid Granulomatosis +

Lymphoplasmacytic Lymphoma +

Medulloblastoma, SHH-Activated +

Medulloepithelioma +

Myelodysplastic Syndromes +

Waldenstrom Macroglobulinemia +

Esophageal Adenocarcinoma +

High Grade Ovarian Serous Adenocarcinoma +

Mature B-Cell Non-Hodgkin Lymphoma +

Osteosarcoma +

Prostate Carcinoma +

Small Cell Lung Carcinoma +

Melanoma +

Solid Neoplasm +

Cervical Carcinoma +

Pancreatic Carcinoma +

Sarcoma +

Gastric Adenocarcinoma +

Soft Tissue Sarcoma +

Bladder Carcinoma +

Diffuse Glioma +

Malignant Glioma +

Central Nervous System Neoplasm +

Renal Cell Carcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Anal Carcinoma +

Anaplastic Astrocytoma, IDH-Mutant +

Anaplastic Ependymoma +

Anaplastic Oligodendroglioma +

Anaplastic Oligodendroglioma, IDH-Mutant And 1p/19q-Codeleted +

Anaplastic Pleomorphic Xanthoastrocytoma +

Atypical Teratoid/Rhabdoid Tumor +

B-Cell Acute Lymphoblastic Leukemia +

Central Nervous System Lymphoma +

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma +

Chronic Myeloid Leukemia +

Clear Cell Renal Cell Carcinoma +

Desmoplastic/Nodular Medulloblastoma +

Diffuse Midline Glioma, H3 K27M-Mutant +

EBV-Positive Mucocutaneous Ulcer +

Embryonal Tumor With Multilayered Rosettes, C19MC-Altered +

Embryonal Tumor With Multilayered Rosettes, Not Otherwise Specified +

Ependymoma +

Ependymoma, RELA Fusion-Positive +

Esophageal Adenosquamous Carcinoma +

Esophageal Squamous Cell Carcinoma +

Extranodal Marginal Zone Lymphoma Of Mucosa-Associated Lymphoid Tissue +

Gastric Adenosquamous Carcinoma +

Gastric Squamous Cell Carcinoma +

Grade 1 Follicular Lymphoma +

Grade 2 Follicular Lymphoma +

Grade 3 Follicular Lymphoma +

Hairy Cell Leukemia +

Head And Neck Carcinoma +

Head And Neck Squamous Cell Carcinoma +

Hematopoietic And Lymphoid Malignancy +

High-Grade Glioma, NOS +

Indolent Non-Hodgkin Lymphoma +

Intraocular Lymphoma +

Large Cell/Anaplastic Medulloblastoma +

Leiomyosarcoma +

Mature T-Cell And NK-Cell Lymphoma/Leukemia +

Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +

Medulloblastoma With Extensive Nodularity +

Medulloblastoma, WNT-Activated +

Neuroblastoma +

Nodal Marginal Zone Lymphoma +

Papillary Renal Cell Carcinoma +

Penile Carcinoma +

Peripheral T-Cell Lymphoma +

Peritoneal Mesothelioma +

Pineoblastoma +

Plasma Cell Leukemia +

Plasmablastic Lymphoma +

Pleural Mesothelioma +

Primary Central Nervous System Lymphoma +

Primary Effusion Lymphoma +

Small Intestinal Lymphoma +

Small Lymphocytic Leukemia +

Small Lymphocytic Lymphoma +

Splenic Marginal Zone Lymphoma +

Vaginal Carcinoma +

Vulvar Carcinoma +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015.

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.